XTCYF (Pegasus Mercantile) Other Long-Term Liabilities: $0.00 Mil (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

What is Pegasus Mercantile Other Long-Term Liabilities?

Pegasus Mercantile XTCYF +18.20% Other Long-Term Liabilities is $0.00 Mil as of Jun. 2026. The stock has 4 warning signs investors should review.

Pegasus Mercantile's other long-term liabilities for the quarter that ended in Jun. 2026 was $0.00 Mil.

Pegasus Mercantile's quarterly other long-term liabilities increased from Dec. 2025 ($-0.00 Mil) to Mar. 2026 ($0.00 Mil) but then stayed the same from Mar. 2026 ($0.00 Mil) to Jun. 2026 ($0.00 Mil).

Pegasus Mercantile's annual other long-term liabilities stayed the same from Sep. 2023 ($0.00 Mil) to Sep. 2024 ($0.00 Mil) but then increased from Sep. 2024 ($0.00 Mil) to Sep. 2025 ($0.00 Mil).

Pegasus Mercantile Other Long-Term Liabilities Related Terms

Pegasus Mercantile Other Long-Term Liabilities Historical Data

* Premium members only.

The historical data trend for Pegasus Mercantile's Other Long-Term Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Pegasus Mercantile Other Long-Term Liabilities Chart

Pegasus Mercantile Annual Data
Trend Sep16 Sep17 Sep18 Sep19 Sep20 Sep21 Sep22 Sep23 Sep24 Sep25
Other Long-Term Liabilities
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 -0.00 0.00 0.00 0.00

Pegasus Mercantile Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Other Long-Term Liabilities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 -0.00 0.00 0.00

Pegasus Mercantile Other Long-Term Liabilities Calculation

Other Long-Term Liabilities are the other liabilities on the balance sheet that do not need to be repaid within the next 12 months, but still need to be repaid over time. For instance, on Wal-Mart's balance sheet, there are items called Long Term obligations under capital leases, deferred income taxes, and redeemable non-controlling interest. These are all Other Long-Term Liabilities.

What does a Other Long-Term Liabilities of $0.00 Mil mean?
Pegasus Mercantile (XTCYF) has a Other Long-Term Liabilities of $0.00 Mil as of Jun. 2026. Other long-term liabilities as record on a company's balance sheet not categorized as standard liabilities. View historical data on Pegasus Mercantile and its competitors.
Is Pegasus Mercantile's Other Long-Term Liabilities too high?
Pegasus Mercantile's current Other Long-Term Liabilities is $0.00 Mil.
How does Pegasus Mercantile's Other Long-Term Liabilities compare to V and MA?
Pegasus Mercantile's Other Long-Term Liabilities of $0.00 Mil can be compared against companies in the Credit Services industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Long-Term Liabilities for a Credit Services company?
A good Other Long-Term Liabilities depends on the Credit Services industry context. However, Other Long-Term Liabilities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Long-Term Liabilities mean?
A high Other Long-Term Liabilities can signal that a stock is expensive relative to its fundamentals. Other long-term liabilities as record on a company's balance sheet not categorized as standard liabilities. View historical data on Pegasus Mercantile and its competitors. Pegasus Mercantile's current Other Long-Term Liabilities is $0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Pegasus Mercantile stock overvalued right now?
Based on GuruFocus' analysis, Pegasus Mercantile (XTCYF) is currently considered Fairly Valued. The stock's GF Value™ is $0.03, compared to a current price of $0.03 — trading 10.2% above its estimated fair value. The current Other Long-Term Liabilities is $0.00 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Long-Term Liabilities calculated?
Other Long-Term Liabilities is calculated from a company's financial statements. For Pegasus Mercantile (XTCYF), the current Other Long-Term Liabilities is $0.00 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Pegasus Mercantile Business Description

Other Exchanges U040:GermanyLOAN:Canada
Address 1100 - 1111 Melville Street, Vancouver, BC, CAN, V6E 3V6
Pegasus Mercantile Inc is a merchant bank focused on the medical cannabis (non-THC), CBD, and hemp sectors in both Canada and the United States. The Company is also focused on specific areas such as pain, depression, and mental illness, investing in pioneering techniques like micro-dosing using organic compounds and synthetic molecules.